CA2224108A1 - Production of value-added milk by incorporation of specific dna sequences into mammary epithelial cells - Google Patents

Abstract

A method is described to transfer a gene encoding a valuable compound, such as apharmaceutical, into the secretory cells of the mammary gland to produce a new compound into the milk or to alter the composition of the milk. In this method the packaging cell line producing the viral-derived particles is infused into the mammary gland. The packaging cells will attach and survive for a period of time within the mammary gland. While the cells are viable, they will supply a continuous source of viral-derived particles to trans-infect the maximum number of mammary epithelial cells. After a period of time in the mammary gland, both the particles and the packaging cells will be destroyed by natural mechanisms while the trans-infected mammary epithelial cells continue to express gene(s) encoding the valuable compound or gene(s) to alter the composition of the milk. One or more genes can be trans-infected including DNA sequences that contribute to the efficient production of an active compound or to its stability. The packaging cells and the viral-derived particles used in this method can be those which trans-infect dividing or non-dividing cells and can be used either singly or together. This method can be used alone or in combination with other novel methods designed to ensure that the viral-derived particles are correctly positioned to trans-infect the mammary epithelial cells. Increasing the trans-infection of the mammary epithelial cells with the viral particles will result in a higher concentration of the valuable compound in the milk.

Description

., Production of Value-added Milk by Incorporation of Specific DNA Sequences into Mammary Epithelial Cells FIELD OF INVENTION
The present invention relates to a method of producing value-added milk by the incorporation of specific DNA sequence(s) into the cells of the mamm~ry gland.
The term "value-added milk" is meant to mean milk containing a valuable compound, 10 such as a pharmaceutical, as well as milk with a changed composition so that the market value of the milk is enhanced.

BACKGROUND OF THE INVENTION
This invention is based upon a technique to transfer a gene, and related non-15 translated control sequences, into the secretory cells of the mammary gland to producenew compounds in milk and/or to alter the milk composition.

An example of a compound produced into milk by this method would be a pharmaceutical which cannot be manufactured in a biologically active state. This20 invention provides an alternative method of producing such pharmaceuticals into milk using the synthetic capabilities of the mammary epithelial cell.

M~mm~l~ produce copious amounts of complex proteins into milk to provide nutrition for their young. To harness this capability, the DNA of, for example a25 valuable pharmaceutical, can be inserted into a mammary epithelial cell and this cell then will produce the active, pharmaceutical compound into the secreted milk. In a cow, the udder will act as a receptacle to hold the milk until it can be collected. The milk cont~ining the added compound can be processed to extract and purify this pharmaceutical compound for subsequent sale, possibly to the medical and/or 30 veterinary communities, or the milk could be consumed directly as a therapeutic agent.

At present there are two basic techniques that can be used to produce value-added milk. The first is to create a transgenic animal by microinjection or transfection 5 of foreign DNA into an ovum or a fertilized egg. Incorporation of DNA at this stage in development generally results in a transgenic animal which carries the inserted DNA in every cell.

There are positive and negative aspects of producing a transgenic animal 10 which expresses foreign proteins in its milk. A positive point is that a single founder animal can create a population of transgenic animals by natural reproduction.
However, progenies do not always produce the exogenous protein at the same level as the original animal. Negative aspects include the technically difficult procedures required to produce the animal and the long time between adding the foreign DNA
15 and harvesting the exogenous protein. In addition, the presence of even very small amounts of an active pharmaceutical in every tissue may be detrimental to the health of the animal.

An alternative method is to produce value-added milk by adding the desired 20 DNA only to the cells of the m~mm~ry gland of the animal. This results in a trans-somatic animal (or chimera) which contains the inserted DNA essentially in only one tissue, the m~mm~ry gland.

Trans-somatic animals have the advantage that they can be produced with less 25 technical difficulty. They also can be produced quickly so that there is a period of only weeks to months between adding the foreign DNA and harvesting the exogenousprotein. Moreover, since only one tissue contains the added DNA and produces theresulting compound, health risks to the trans-somatic animal are reduced. Although the DNA is not passed on to the progeny, this is compensated for by the ease and30 speed with which a trans-somatic animal can be produced.

A trans-somatic goat which expresses human growth hormone (hGH) into milk has been produced by Archer et al. (1994). In Archer the viral-derived particles were infused into the m~mm~ry gland for approximately every two days for two weeks. The levels of the compound, human growth hormone, which was used as an 5 example, were very low and approached background levels after the first day. Also Gould et al. (United States Patent 5,215,904) described a method for increasing the rate of mitosis of m~mm~ry epithelial cells and then exposing these cells to viral particles for integration of the desired DNA into the epithelial cell.

To produce either a trans-somatic or a transgenic animal, exogenous DNA
must pass through the exterior cell membrane. Eukaryotic cells have evolved a membrane which is impervious to most substances including heterologous DNA.
Numerous techniques have been developed to bypass this barrier. These include:
electroporation, carrier lipids (liposomes, negative, positive or neutral charged vesicles), mechanical wounding of cells including microinjection, liquid or airjet pressure and scrape loading, use of particles composed partially or wholly of viral proteins.
Methods which have successfully produced trans-somatic animals include:
1) Arterial injection of DNA carried in liposomes (small lipid vesicles) was used to produce a trans-somatic mouse (Thierry et al. 1995). This technique can be adapted to deliver DNA to the m~mm~ry gland by injection into the major artery 25 serving the m~mm~ry gland but circulation of the blood carrying the DNA can result in transfection of multiple tissues.

2) Direct injection of the DNA into tissues was used successfully to add foreign DNA to muscle and other tissues (Furth et al. 1992). This technique can be adapted to inject virus-like particles, carrying the foreign DNA, directly into the tissue 30 of the udder.

3) Use of viral-derived particles carrying DNA coding for human growth hormone (hGH) were infused through the teat canal, for example by Archer et al.
(1994). This resulted in production of trans-somatic goats which expressed hGH into the milk.

Viruses reproduce within cells and therefore have evolved a technique to by-pass the protective cell membrane to deliver the viral genome (DNA) into a host cell.
To enter a cell, protein(s) of the outer viral shells first bind to receptors on the cell surface and then the virus is internalized.

The method used by Archer involves transfecting a cell line with DNA coding for various, but not all, proteins of a virus. This cell line, called a "packaging cell line", will produce empty virus shells which can bind to receptors on the host cell membrane. When heterologous DNA, coding for a pharmaceutical or other milk modification, is transfected into the packaging cell line, this DNA will be packaged into the viral-derived particle. When the viral-derived particle comes in contact with a milk-producing cell, the viral proteins of the shell ensure that the heterologous DNA
is carried into the cell. Other viral proteins, associated with the particle, integrate the heterologous DNA into the genome of the host cell so that the protein encoded by the DNA can be expressed. In this method the viral-derived particles are used to introduce the heterologous DNA into the m~mm~ry gland.

The trans-somatic methods of the prior art offer advantages over the transgenic method; however the very low levels of foreign protein in the milk of the trans-somatic animal have limited the commercial success of these methods.
Thus the present invention is directed to methods of improving the yield of the foreign protein in the milk of a trans-somatic animal.

SUMMARY OF THE INVENTION
The present invention relates to a method of producing valuable compounds into milk and/or ch~nging the composition of milk so as to enhance its properties and/or its marketability. More specifically the present invention relates to the addition of specific DNA sequences, including non-translated regulatory sequences, to the cells of the m~mm~ry gland and the subsequent expression of compound(s) encoded by that DNA into the milk. Other DNA sequences that enhance the efficiency of production5 of the compound, enhance the stability of the compound, or result in biological activity of the compound can also be added to the m~mm~ry epithelial cells either at the same time or at a different time.

The novel method of the present invention involves the use of viral-derived 10 particles and packaging cells which produce these particles for infusion into the m~mm~ry gland through the teat canal. The packaging cells will attach and survive for a period of time within the m~mm~ry gland. While the cells are viable, they will supply a continuous source of viral-derived particles. These viral-derived particles trans-infect only dividing cells and are destroyed relatively quickly in the m~mm~ry 15 gland. Thus a continuous supply of viral-derived particles from the packaging cells present in the m~mm~ry gland will ensure that viral-derived particles are present and can trans-infect the m~mm~ry epithelial cells whenever they divide.

The packaging cells and viral-derived particles can be from retroviruses and 20 from non-retroviruses. Most retroviral-derived particles trans-infect only dividing cells. Non-retroviral particles such as those from adenovirus, Epstein-Barr virus, or other viruses trans-infect non-dividing cells. Thus a mixture of the two types of particles, and the associated packaging cells if needed, will ensure delivery of the packaged DNA to the maximum number of cells. Moreover, DNA can be packaged 25 into viral-derived particles in vitro and these can be used for trans-infection as well.

This method can be used alone or in combination with other novel methods designed to ensure that the viral-derived particles are correctly positioned to trans-infect the m~mm~ry epithelial cells. Increasing the trans-infection of the m~mm~ry 30 epithelial cells with the viral particles will result in a higher concentration of the valuable compound in the milk along with possible other compounds produced from the inserted DNA that will enhance the efficient production, stability or activity of the compound.

Thus according to the present invention there is provided a method of producing a trans-somatic m~mm~l, wherein said method provides the incorporationof a DNA sequence into the secretory cells of the m~mm~ry gland to alter the composition of the milk, comprising the steps of: providing a vector cont~ining a DNA sequence encoding a valuable compound; packaging said vector into a cell line;
preparing a solution comprising the packaged vector and cell line producing saidpackaged vector; and delivering said solution into the m~mm~ry gland to allow the incorporation of the DNA into the secretory cells of the m~mm~ry gland.

BRIEF DESCRIPTION OF THE DRAWINGS
These and other features of the invention will become more apparent from the following description in which reference is made to the appended drawings wherein:
FIGURE 1 shows the presence of arnylase in an udder infused with Clone 10 (left hind quarter) and Clone 12 (right hind quarter). The left front quarter was leftuntouched as a negative control and the right front quarter was infused with DMEM
and Polybrene but no cells, to serve as a further negative control. Lanes l, 2 &3, early premilk from 3 quarters of cow #99. Lane 1, control quarter (RF-); Lane 2, treated quarter (RH+); Lane 3, treated quarter (LH+). Lanes 4, 5 & 6, late premilk from cow #99. Lane 4, treated quarter (LH+); Lane 5, treated quarter (RH+); Lane 6, control quarter (RH-). Lane 7, mixture of pig and chicken amylase standards; Lane 8, chicken amylase standard.
FIGURE 2 is a Western blot showing the presence of tPA in an udder infused with Clone 1. Lane 1, premilk from treated quarter (LH+) of cow #56; Lane 2, premilk from control quarter (LF-) of cow #56; Lane 3, premilk from treated quarter (RF+) of cow #90.

DESCRIPTION OF THE PREFERRED EMBODIMENT
The present invention relates to a method to transfer a gene or genes, and related non-translated control sequences into the secretory cells of a m~m m~ry gland to produce "value-added milk". The term "value-added milk" is meant to mean milkcontaining a valuable compound, such as a pharmaceutical, as well as milk with achanged composition so that the market value of the milk is enhanced.

Pharmaceuticals according to the present invention can include, but are not limited to: a tissue plasminogen activator, a blood clotting factor, an antibody, a protein to aid in weight reduction, a galactosyltransferase, a growth factor, anoncoprotein, a protease inhibitor, a hormone, a milk protein, a hormone receptor, a 10 tumor suppressor protein, an aging inhibitor, or an erythropoietin.

According to the present invention there is provided a suitable DNA vector (plasmid) containing the desired DNA sequence encoding the heterologous protein (valuable compound) and associated regulatory sequences such as promoters, 15 enhancers, introns, signal sequences, etc. Other sequences to produce compounds that increase efficient production, enhanced stability or are involved in biological activity of the compound can be included in the same or another DNA vector.

In one embodiment the vector is based on the pLXSN, pLNCX, or pLNSX
20 plasmids provided under license from Fred Hutchinson Cancer Research Center.

According to the present invention the delivery of the DNA to the cells of the m~m m~ry gland is accomplished by the use of viral-derived particles and packaging cells, which produce these particles, for infusion into the m~m m~ry gland through the 25 teat canal. This infusion is a standard veterinary practice and usually involves the use of a cannula for insertion into the teat canal, the cannula being attached to a syringe containing a solution of the packaging cells and viral-derived particles.

It has already been established that such particles derived from retrovirus 30 trans-infect only dividing cells. Thus, the infusion of the particles and the packaging cells takes place when m~m m~ry cell division is naturally at a high level. In the present invention heifers at 5 to 7 months pregnancy were used. It would also bepossible to use non-pregnant m~mm~ls treated with hormones to induce m~mm~ry cell division and lactation prior to particle and cell infusion. However, this method would involve additional handling of the animal and thus is not preferred.

Other types of viral-derived particles and associated packaging cell lines, suchas those based on adenovirus, Epstein-Barr virus, or other viruses can also be used.
These non-retroviral derived particles can infect non-dividing cells. If used incombination with the retroviral derived particles described above, the maximum 10 number of cells will receive the desired DNA. In addition, particles to deliver DNA
can be manufactured in vitro and use of these alone or in combination with the above described particles will enhance the number of m~mm~ry epithelial cells which incorporate the desired DNA. An example of particles which are constructed in vitro is described or referred to in Morsy and Caskey (1997).
The present invention is applicable to all m~mm~ls and is especially applicable to all non-human m~mm~l.s. Goats, sheep and cows are preferred. Cows with their inherent large volume milk production are particularly preferred.

The packaging cells will attach and survive for a period of time within the m~mm~ry gland. The reason for the presence of the cells is to supply a continuous source of the viral-derived particles to trans-infect the maximum number of m~mm~ry epithelial cells. Both the packaging cells and the viral-derived particles are eventually destroyed in the m~mm~ry gland; however, considering the fragile nature of the particles in vitro, they are likely destroyed within days. The cells, by contrast, may persist much longer. When cells were infused into the udder, and the udder subsequently flushed and assayed for the presence of cells (dead and alive), most of the cells could not be flushed out. Cells were seen in the wash for 3 days afterinfusion, of those cells that were flushed out, a large majority remain viable, suggesting that most of the cells have become attached to the udder. In prior art methods (for example Archer et al. 1994), the particles are infused into the udder approximately every two days for two weeks. In the present invention no subsequent infusions are necessary. Thus an advantage of the present invention over the prior art is a reduction in the handling of the animal.

In prior arts methods (for example, Archer et al. 1994), large scale tissue culture was required to supply sufficient numbers of particles for multiple infusions.
An advantage of the present invention over the prior art is that preparation of a large number of particles is not required.

In prior arts methods (for example, Archer et al. 1994), the preparation of a stock solution of viral-particles required ultra-centrifugation and resuspension of the particles. A further advantage of the present invention is that no ultracentrifugation is involved. Centrifugation and other handling techniques can destroy the relatively fragile particles. In the present invention, handling of the particles is minim~l, increasing the probability that the particles present will remain intact and useful.

The above cited advantages are in addition to the improvement in yield of the compound in the milk, which has already been described above.

This method can be used alone or in combination with other methods of the present invention to increase the incorporation of DNA from the viral-derived particles. The additional methods of the present invention are all designed to ensure that the viral-derived particles are correctly positioned to trans-infect the m~mm~ry epithelial cells.
In one embodiment, the teat canal and udder is first emptied by milking or under negative pressure. Then the udder is flushed with an osmotically-balanced solution which is infused into the teat canal and udder until the udder is full. This solution is removed by milking or under negative pressure and the desired suspension is infused into the udder. In an alternative procedure, the teat canal is not emptied first but is directly filled with an osmotically-balanced solution which is then removed by milking or under negative pressure.

Flushing of the udder serves two purposes; it removes the thick, secreted fluid that is normally present and it forces open the ductwork to allow better access of the 5 packaging cells and viral-derived particles which will be inserted in the next step of the procedure. An example of a suitable osmotically-balanced solution includes saline solution, but can include any other buffered solutions, and also can include thepackaging cell grown medium.

External massage applied several times a day to the m~mm~ry gland improves the circulation of the viral-derived particles and results in more secretory cells in the m~rnm~ry gland being exposed to the viral-derived particles and thus more cells will incorporate the DNA carried in these particles.

In another embodiment, the packaging cells are grown on a commercially available matrix (designed to support growth and replication of tissue culture cells).
This solid support matrix can include gelatin, glass, collagen or plastic beads.Cytodex beads or Cultisphere (purchased from Sigma) are two specific examples ofuseful support means. The beads, with cells adhering to them, are infused into the 20 m~mm~ry gland through the teat canal along with a suspension of DNA-containing viral-derived particles. The beads remain in the m~mm~ry gland. External massageapplied several times a day to the m~mm~ry gland recirculates the beads and helps to distribute the viral-derived particles that are produced by the packaging cells growing on the beads. The presence of the packaging cells on beads also ensures the 25 continuous presence of many more DNA-containing viral-derived particles.
Concomitantly more secretory cells in the m~mm~ry gland will incorporate the DNAcarried within these viral particles and the production of the desired protein will increase accordingly. The beads and any cells rem~ining on them will eventually be removed when milking is begun.
In another embodiment, the infusion of cells (with or without growth on beads) and viral-derived particles containing the desired DNA is followed by infusion of a substance which is more dense than the water-based suspension fluids, used for cell infusion, such as growth medium (Dulbecco's modified Eagle's medium [DMEM], phosphate buffered saline [PBS], etc.). This dense fluid, which in one 5 example is composed of silicone, displaces the aqueous solutions containing the packaging cells and the viral-derived particles upwards into the ductwork of themamm~ry gland. This prevents collection of the packaging cells in the cistern of the udder and positions the viral-derived cells and the viral-derived particles up into the ducts of the mamm~ry gland. Thus, the viral-derived particles are positioned near the 10 dividing cells in the alveoli of the m~mm~ry gland and allow more of the DNA
carried in the viral-derived particles to be incorporated. Any physiologically compatible inert fluid that has a density greater than that of the infusion solution can be used according to this embodiment of the present invention.

Thus, the present invention consists of the following procedure, which can be used alone or in combination with optional methods of the present invention, to deliver heterologous DNA to milk producing cells. In this procedure the following steps occur:
1) A vector containing the desired DNA sequence(s) is constructed and is 20 transfected by standard means into a packaging cell line.
2) A solution containing the packaging cell line, producing viral-derived particles cont~ining the desired DNA sequence(s), and viral-derived particles, is infused into the mammary gland through the teat canal. The packaging cells attach to the epithelial cells of the m~mm~ry gland, remain viable and produce viral-derived 25 particles.
3) The DNA becomes incorporated into the secretory cells of the mamm~ry gland.

4) The milk containing the product induced by addition of the desired DNA
is milked from the cistern. The product is purified from the milk or the milk, 30 containing the product, is consumed.

The basic technique can be modified by the addition of one or more of the following steps:
1) The udder is flushed with an osmotically-balanced solution.
2) The packaging cells are grown on a matrix designed to support proliferation of eukaryotic cells, such as Cytodex beads, and then infused through the teat canal. The cells will remain in the m~mm:~ry gland and continue to produce viral-derived particles for a period of at least 3 days.
3) After infusion of the packaging cells (either as a suspension or grown on a matrix), a compound which is denser than aqueous solutions, such as silicone, isinfused into the m~mm~ry gland to force the aqueous solutions carrying the packaging cells and viral-derived particles up and into the region of the m~mm~ry gland where the DNA can be incorporated into the milk producing cells. The dense compound, if it has been added, and any unattached cells as well as the matrix, if used, is removed from the m~mm~ry gland cistern by milking at an appropriate time after infusion. An appropriate time is defined as after the majority of packaging cells attach and after there is sufficient production of viral-derived particles. An example of an appropriate time would be at least 3 days, however shorter or longer periods may also be used.
The packaging cells which are not removed at this time die and are removed by the recipient's natural mech~ni~ms.
4) External massage applied several times a day to the m~mm~ry gland will recirculate the viral-derived particles and the packaging cells, provided either as a suspension or grown on a matrix. This helps to distribute the viral-particles and the cells and increases the incorporation of the DNA carried in these particles into the secretory cells.
While this invention is described in detail with particular reference to preferred embodiments thereof, said embodiments are offered to illustrate but do not limit the invention.

EXAMPLES
Example 1: Preparation of plasmids carrying the desired gene and various control sequences for use in retroviral particle delivery to bovine m~ m~ry epithelial cells As a system to transfect the m~rnm~ry epithelial cells with a desired gene, the PG13 packaging cell line was acquired under license from Fred Hutchinson Cancer Research Center. This system was used because it produces retroviral particles cont~ining the gibbon ape leukemia virus envelope (Galv) which facilitates transfection of bovine cells. To package the desired gene "X" into retroviral particles, the plasmids, pLXSN, pLNCX, pLNSX and pLN, also were acquired under license from Fred Hutchinson Cancer Research Center.

Modifications of plasmids:
In order to have an alternative method to select cell clones cont~ining the desired gene, we replaced the neomycin (neo) gene with the hygromycin (hyg) gene in pLXSN, pLNSX and pLNCX. This was done by long-range PCR-amplification of the region around the neo gene then ligating the PCR product with the hyg gene whichwas amplified from the plasmid pREP4 (purchased from Invitrogen). The resulting plasmids were called pLXSH, pLHSX and pLHCX where "L" represents the Moloney murine virus long terminal repeat (LTR) acting as a promoter, "S" is the SV40 promoter and "C" is the cytomegalovirus promoter region.

To put the desired gene, "X", under the control of a constitutive promoter, the cytomegalovirus promoter region in pLNCX and pLHCX was removed by restriction digestion and replaced with the beta actin promoter to make pLNAX and pLHAX.
The beta actin promoter sequence was derived using PCR from the pJ6Q plasmid purchased from ATCC (catalog no. 37723).

In order to avoid transcription interference between the gene used for selectionand the gene used to produce the desired protein, transcription from both genes was coupled by replacing the SV40 promoter from the plasmids pLXSN and pLXSH with an internal ribosomal entry site (IRES). The resulting plasmids, pLAiN and pLAiH, express both the selection gene and the inserted gene under the same (LTR) promoter.
The IRES in these plasmids provides the translation initiation site within the transcriipt, allowing the downstream gene product to be produced. The IRES used 5 here is identical to the IRES found in the plasmid pIRES 1 neo purchased from Clontech. The sequences for pLAiN and pLAiH, where A in this case is chicken amylase but which can be any desired protein, are shown in SEQ ID No: 1 and SEQ
ID No: 2, respectively.

In order to increase retroviral titre or stability of the transcript, or to increase the expression level of the desired gene during lactation, or to allow translation of more than one protein from the same transcript, the basic plasmid, pLNCX, was modified. In one modification, the selection gene was removed to minimi7e the size of the resulting plasmid, pLX. In another modification, the CMV promoter was 15 replaced with the murine m~mm~ry tumour virus (M) LTR promoter to improve transcri.ption of the resulting plasmid, pLNMX, during lactation. The sequence for pLNMX is shown in SEQ ID No: 3.

In another modification, a wild-type IRES was modified so that the ATG
20 codon .~t position 10 is destroyed and the sequence downstream of the ATG codon at pOSitiO]1 11 codes for the desired gene, "X", in a plasmid such as pLNMi2X. The sequence for this IRES modification (i2) is included within the sequence for pLNMii2X, shown in SEQ ID No: 4.

25 Example 2: Preparation of cell clones producing viral-derived particles carrying the chicken amylase gene as a "marker" protein The two packaging cell lines used in this experiment were purchased from ATCC, PA3 17 (catalog no. CRL-9078) and PG13 (catalog no. CRL-10686). A
description of both PA3 17 and PG13 and their use can be found in Miller et al. 1990.
To develop and optimize the transfection of m~mm~ry epithelial cells using the retroviral particle delivery system, we used a stable and readily detectable marker protein, chicken amylase, in some experiments. Chicken amylase migrates at a unique position by native gel electrophoresis and can be differentiated from bovine or other amylases. To produce a PG13-derived cell line (a clone) producing retroviral S particles which carried chicken amylase under the control of the beta actin promoter, the following procedure was done.

The pLH(A)amy plasmid with hygromycin (H) driven by the LTR promoter and with amylase (amy) driven by the beta actin promoter (A), was produced by standard recombinant techniques. pLH(A)amy was transiently transfected by the calcium phosphate technique into the PA317 packaging cell line. The transfected PA317 cells produce viral particles cont~ining the amy RNA into the supernatant.The amphotropic viral envelope protein of these particles allows entry into cells of most species including the PG13 packaging cells in a process called trans-infection.
Empirically it has been determined that trans-infection produces PG 13 clones with a higher rate of particle production as compared to PG13 clones produced by other means of DNA insertion (particle bombardment, calcium phosphate or liposome transfection). Therefore, the viral-derived particles in the supernatant of the transfected PA317 cells were used to trans-infect the PG13 packaging cell line. The resulting clones were selected using 700 ug/ml hygromycin in DMEM with 10% fetalbovine serum (FBS) and 1% penicillin/streptomycin for 14 days. Clones were picked using cloning rings and grown as separate cell lines.

These PG13 amy clones were tested for amylase production by native gel electrophoresis of c~-amylase. The oc-amylase samples in loading buffer (O.lM tris-borate pH 8.5, 10% sucrose, lOmM magnesium chloride) were electrophoresed for 3-4 hours at 250 volts, with cooling, on a 5.5% acrylamide gel containing O.lM tris-borate pH 8.5. The electrophoresis buffer was O.lM tris-borate pH 8.5. The gel was then placed with gentle ~h~king for 1 h at room temperature in a solution of 2%
soluble starch, lOmM calcium chloride, 50mM tris-HCl pH 7.5. The gel was brieflyrinsed in water, then placed in a dilute solution of iodine (I2: KI: water is about 1: 2:

2000) lmtil the amylase signal shows as a clear band on the gel.

All packaging cells produce filled retroviral particles which contain the desired gene and empty particles which do not carry the desired gene. To increase the number 5 of filled retroviral particles, hygromycin-resistant PG13 amy clones producing high amounts of amylase were supertransfected with a second plasmid, pLN(A)amy, which also carried the amylase gene but which has neomycin as the clone selection agent. In this procedure, first pLN(A)amy was transfected into the PA3 17 cell line by the calcium phosphate procedure, and then the viral-derived particles in the l O supern:lt~nt of the transfected PA3 17 amy-cont~ining cells were used to trans-infect a PG13/pLH(A)amy clone. The PG13/pLH(A) clone which was supertransfected was chosen on the basis of high amylase production. Superclones, cont~ining both pLN(A)amy and pLH(A)amy sequences were obtained by selecting in the presence of 1000 ug/ml G418 and 700 ug/ml hygromycin as described above. The surviving 15 clones were picked and grown up for further testing. Although a marker protein, amylase, was used in these experiments to optimize filling of particles, it is obvious that the same procedure can be done where another protein, such as a pharmaceutical protein, is used instead of the amylase.

The superclones producing the highest levels of amylase were analyzed for particle production by the following method. For each clone to be tested, the supernatant containing viral-derived particles was used to trans-infect HeLa 229(human cervical carcinoma) (purchased from ATCC catalog no. CCL-2. 1 ) and Et2 (bovine m~mm:~ry) cells (provided by Dr. Boris Zavizion, University of Vermont, Burlingrton, Vt.). Depending on the resistance gene contained in the plasmid, the trans-infected cells were treated with either 700 ug/ml hygromycin or l O00 ug/ml neomycin, or both, and the resulting colonies were counted. Each colony is the result of one infective (filled) particle. The clone producing the highest number of colonies was selected to be grown for subsequent infusion into the heifer udder. In the specific example shown in Figure 1, clone 10 produced the highest number of viral-derivedparticles and was designated as PG13/LH/LN(A)amy.

Before a clone can be infused into the udder, it must be tested to determine that it cloes not produce replication-competent (called "helper") virus. Gene therapy is based on the assumption that the viral-derived particles can carry the desired DNA
(i.e. cDNA for amylase or another protein) into the target cell but that once in the cell, the virus cannot reproduce itself. There are two methods to check if helper virus is being produced by the trans-infected packaging cell line. These are described indetail in Cepko, 1992. The first method is to analyze the supernatant of the HeLa and Et2 cells for horizontal spread of hygromycin and/or neomycin resistance. The second method is to look for the presence of reverse transcriptase above background levels in the supernatant of the trans-infected HeLa and Et2 cells. If trans-infection with the supernatant from HeLa and Et2 cells does not produce hygromycin and/or neomycin resistant colonies and if there is no reverse transcriptase above the level found in control cells, then it can be assumed that the particle producing clone, in this case PG13/LH/LN(A)amy, is not producing "helper" virus and therefore can be usedfor infusion into the udder. We followed the procedures detailed in the Cepko reference and found neither colony nor reverse transcriptase production.

Example 3: Infusion of clones producing retroviral-derived particles which carrya desired gene such as the amylase marker protein In one example, the cell clone PG13/LH/LN(A)amy, which expresses chicken amylase as a marker protein, was infused into the udder of a 7 month pregnant heifer, #99. E~efore infusion with the cell clone, each quarter of the udder was flushed with 250ml of saline solution at 37~ C using the catheter portion of an angiocath G-18 catheter attached to a 140 cc Monoject syringe with a Luer lock attachment (bothpurchased from CDMV, Saint-Hyacinthe, Quebec). The infusate was then milked out and measured to determine the volume of cell solution which could be ~ministered to this particular quarter of this specific heifer.

Two superclones, designated as PG13/LH/LN(A)amy Clone 10 and PG13/I,H/LN(A)amy Clone 12, were grown in standard tissue culture flasks until the total cell number (in an appropriate number of flasks) was >2 x 108 cells/clone. The cells were trypsinized, counted and resuspended at 1 x 108 cells in 250 ml DMEM
without serum but cont~ining 80 ug/ml of Polybrene to facilitate particle adsorption to the m~mm~ry epithelial cells.

The udder has four separate quarters. The left front quarter was left untouched as a negative control (LF-). The front right quarter was flushed with saline andinfused with 250 ml DMEM plus 80 ug/ml Polybrene but with NO cells added and served as a negative control (RF-). The right hind quarter was infused with 1 x 1 o8 Clone L2 cells in 250 ml DMEM plus Polybrene (RH+) and the left hind quarter wasinfused 1 x 108 Clone 10 cells in 250 ml DMEM plus Polybrene (LH+). The infusatewas not removed. The udder was massaged 3 times a day, morning, noon and night, to help to distribute the cells which tend to settle into the cistern of the udder. Three weeks post infusion, the udder was "stripped" (all secretions were milked by hand from each quarter) which removed about 7 to 10 ml per quarter of a viscous, serum-like fluid. This was designated as "early premilk". Eight weeks post infusion the udder was stripped again, producing about 25 ml per quarter of a slightly cloudy, viscous fluid designated as "late premilk". The samples from the right front control quarter RF(-) and the two infused quarters, the right hind, RH(+) and the left hind, LH(+) were analyzed for the presence of active amylase as previously described (see Figure 1).

Figure 1 shows that in the early premilk sample, amylase is present in both infused quarters (RH) and (LH) while the control quarter (RF) contains no amylase.
In the late premilk, the negative control quarter (RF) continues to show no amylase activity. Clone 10, left hind quarter, shows the highest amylase activity. Clone 12, right hind quarter, has decreased activity compared to the early premilk sample, but a small amount of amylase activity was detected. The samples loaded represent equal volumes (100 ul/lane) ofthe premilk samples. No attempt was made to load equal amounts of protein. The apparent reduction in the amount of amylase present between early and late premilk samples is caused by increased volume of the late premilksamples relative to the volume of the early premilk samples.

Example 4: Preparation of a clone producing viral-derived particles that carry the tPA gene and infusion of this clone into the udder of a pregnant heifer Tissue plasminogen activator (tPA) is used to treat heart attack and stroke by 5 dissolving blood clots. We selected human tPA to be the first pharmaceutical product to be produced by our method in bovine milk. The ptPA-K plasmid, containing the mutated cDNA sequence for human tPA (where the amino acids KHRR 296-299 was mutated to AAAA, i.e. the "K" mutation), was purchased *om ATCC (American Type Culture Collection, catalog no. 68059). Two additional mutations were 10 incorporated into ptPA-K to form ptPA-TNK: the amino acid threonine at position 103 was mutated to asparagine (the "T" mutation), and the amino acid asparagine at position 117 was mutated to glutamine (the "N" mutation). The tPA amino acid sequence and a description of the above modifications can be found in Pennica etal.1983. Both mutations were produced by using mi~m~tched oligonucleotides 15 containing the altered nucleotide sequence as primers for PCR amplification. The tPA-TNK gene was subsequently excised by restriction digestion and ligated into the pLXSH plasmid to make pL(tPA)SH.

The resulting PG13(tPA) clones were analyzed for tPA production by 20 colorimetric determination using Spectrozyme (# 444 purchased from American Diagnostica Inc.). Clones which showed high levels of tPA were then checked for produc-tion of filled particles by colony counts (as described previously) and were safety checked to insure that no replication competent virus was being produced and that there was no reverse transcriptase production above that found as background in 25 HeLa or ET2 cells. None of the clones tested produced replication competent virus by either of these tests. The clones with the highest particle production and highest level of tPA production were selected to be grown for infusion into the udder. In the following example, clone PG13/L(tPA)SH-1, was chosen for infusion into the udder.

Inoneexample, Clone 1 (PG13/L(tPA)SH-l),whichproducestPA,was infused into the udder of a seven and a half month pregnant heifer, #90 and into the udder of a six and a half month pregnant heifer, #56. Before infusion of the clone and particles produced by it, each quarter of the udder in both heifers was flushed with 250ml of saline as described in Example 3. After milking out the saline, the right rear (RR) quarter of heifer #90 received 2.5 x 107 cells of Clone 1 plus 80 ug/ml Polybrene in 250 ml of DMEM without serum while the right front (RF) quarter received 1 x 1 o8 cells of Clone 1 plus 80 ug/ml Polybrene in 250 ml of DMEM without serum. The left front (LF) quarter received 250 ml of DMEM as a control while the left rear (LR) quarter was the untreated control. Heifer # 56 received 2.5 x 107 cells of Clone 1 plus 80 ug/ml Polybrene in 250 ml of DMEM without serum in the left front quarter (LF+) and 1 x 108 cells of Clone 1 plus 80 ug/ml Polybrene in 250 ml of DMEM without serum in the right rear quarter (RR+). The right front quarter received 250 ml of DMEM as a control (RF-) while the left front (LF-) quarter was the untreated control.
In both heifers, the infusate was not removed and the udder was massaged three times daily to help distribute the cells and particles up into the ductwork.
Four weeks post-infusion, the four quarters of both heifers were stripped to remove 5 to 9ml of the viscous, serum-like premilk fluid. The premilk samples from treated and control quarters of both heifers were analyzed for the presence of tPA by Western blotting. A Western blot showing the tPA results obtained from the best quarter of each heifer is shown in Figure 2.

For Western blotting, the premilk samples were adjusted to pH 4.5 with acetic acid and centrifuged at 13,000 x g to pellet the "curd" fraction. The "whey" fraction contained in the supernatant was collected and diluted 1 :5 with sample buffer.
Samples of 20 ul were loaded onto a 7.5% SDS PAGE gel. To detect tPA, the gel was transferred to nitrocellulose and then blocked overnight in 5% bovine serum albumin (BSA). The blot was incubated for 2 hours with a polyclonal antibody to tPA, #385R, purchased from American Diagnostica, diluted 1 :500 with PBS followed by extensive washing in PBS. The secondary antibody, horseradish peroxidase goat-anti-rabbit, diluted 1 :5000 in PBS, was incubated with the blot for one hour then extensively washed. Detection of antibody staining of tPA was by enhanced chemi-luminescence (ECL) Amersham Detect Kit. Specificity of the primary antibody was previously determined by Western blotting a control sample of commercial tPA
purchased from American Diagnostica.

Results of Western blotting samples obtained from the untreated control quarter (LF-) and from one treated quarters of each heifer are shown in Figure 2.
Lane 1 shows a strong tPA band in the premilk from the treated (LH+) quarter of heifer #56. The middle lane, lane 2, contains premilk from the (LF-) control quarter of cow #56. Lane 3 shows a tPA band in the premilk from the treated (RF+) quarter of heifer #90. A faint smear in all 3 sample lanes is the result of non-specific binding of the antibody to an unidentified protein and should be disregarded.

Example ~: Determination of viabilitv and attachment of 3T3 cells to the surfaceof the bovine udder.
The cells used in this experiment were 3T3 cells (purchased from ATCC, catalog no. CCL-92) which had been transfected with luciferase as a marker protein.
These 3T3 cells are essentially identical to the PG13 packaging cells except that the 3T3 cells have not been transfected with the retroviral genes that are found in the packaging line.

Three quarters of the udder of a 5 month pregnant heifer and three quarters of the udder of a 7 month pregnant heifer were flushed with saline solution at 37~ C
using a standard veterinary infusion apparatus. The saline was then milked out and measured to determine what quantity of medium with or without cells could be infused into that particular quarter. In both heifers, one udder quarter was left untreated as a negative control, a second quarter received only DMEM, the third quarter received 1 X 1 o6 cells suspended in an appropriate amount of DMEM, and the fourth quarter received 1 X 107 cells also suspended in an appropriate amount ofDMEM. The quarters were then milked to produce about 10 ml of fluid at 3 hours, 24 hours, and 72 hours post-infusion.

The fluid obtained by milking was divided in half. One portion was cultured under standard conditions for 3T3 cells to determine if the cells were viable. The second portion was used in a luciferase assay to count the approximate number of3T3-luciferase cells per ml in the fluid. A control was run simultaneously using5 known numbers of 3T3-luciferase cells and a curve drawn to determine the correlation of luciferase intensity with cell number.

The results of two experiments indicated that the highest number of cells were found 3 hours post infusion and progressively fewer cells were found in the fluid 10 milked from the udder at 24 and 72 hours. However the cells which were milked out at 72 hours were viable. This is evidence that the cells are attaching to the udder surface and that those cells which were unattached (and therefore could be milked out of the udder) remained viable for the period of the experiment. This suggests that the 3T3 cells are not quickly destroyed by the factors in the environment of the udder.
15 Thus PG13(tPA) cells can be expected to remain viable for at least a period of 3 days during which time they will continue to produce viral-derived particles and can therefore trans-infect a substantial number of m~mm~ry epithelial cells.

Table 1: Attachment of 3T3 cells to udder walls Attachment of 3T3 cells to udder interior at:
UdderQuarter Treatment 3 hours 24 hours 72 hours post-infusion post-infusion post-infusion left hind no treatment left front medium only right hind 1 X 106 cells - +/- +
right front 1 x 107 cells +/- ++ ++

Example 6: Infusion of 3T3 cells grown on a solid support means The cells used in this experiment were 3T3 cells, as described in Example 2.

In this example however the cells were grown on Cytodex beads.

The cells growing on beads were infused into the udder of a 7 month pregnant heifer and subsequently removed 1, 2 and 3 days later as described in Example 2. Cells 5 were removed from beads and viability was determined by Trypan blue exclusion. The cells remained viable for the entire period.

E~ample 7: Use of Silicone to displace the cells and viral-derived particles The cells used in this experiment were 3T3 cells, as described in Example 3.
10 The volume of the solution containing the cells and viral-derived particles was reduced by 50 ml, 25 ml, or 10 ml but the overall number of the cells remained constant.

After the solution was infused into the udder, as described in the preceding examples, approximately 50 ml, 25 ml or 10 ml of silicone was infused into the m~mm~ry gland, using the methods previously described.

After three days the silicone was removed from the cistern by milking. No reaction to the silicone was noted.
All scientific publications and patent documents are incorporated herein by reference.

References:
Archer, J.S., W.S. Kennan, M.N. Gould, R.D. Bremel. 1994. Human growth hormone (hGH) secretion in milk of goats after direct transfer of the hGH gene into the m:~mm~ry gland by using replication-defective retrovirus vectors. Proc. Natl.
Acad. Sci. USA, 91 :6840-6844.
Cepko, C. 1992. Transduction of genes using retrovirus vectors. In: Short Protocols in Molecular Biology, 2nd edition. Ed. F.M. Ausubel, R. Brent, R.E. Kingston, D.D.
Moore, J.G. Seidman, J.A. Struhl. Pub. by John Wiley & Sons. New York, N.Y. pp 9-30 to 9-45.

5 Furth, P.A., A. Shamay, R.J. Wall, L. Henningh~ sen. 1992. Gene transfer into somatic tissues by jet injection. Analyt. Biochem. 205 :365-368.

Miller, A.D., D.G. Miller, J. V. Garcia, C.M. Lynch. 1990. Use of retroviral vectors for gene transfer and expression. Meth. Enzymol. 217: 581-599.
Morsy, M.A. and C.T. Caskey. 1997. Safe gene vectors made simpler. Nature Biotech. 15: 17.

Pennica, D, W.E. Holmes, W.J. Kohr, R.N. Harkins, G.A. Vehaar, C.A. Ward, W.F.
15 Bennett, E. Yelverton, P.H. Seeburg, H.L. Heyneker, D.V. Goeddel. 1983. Cloning and expression of human tissue-type plaminogen activator cDNA in E. coli. Nature301: 2]4-221.

Thierry, A.R., Y. Lunardi-Iskandar, J.L. Bryant, P. Rabinovich, R.C. Gallo, L.C.20 Mahan. 1995. Systemic gene therapy: Biodistribution and long-term expression of a transgene in mice. Proc. Natl. Acad. Sci. USA. 92:9742-9746.

The present invention has been described with regard to preferred embodiments. However, it will be obvious to persons skilled in the art that a number 25 of variations and modifications can be made without departing from the scope of the invention as described in the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: Her Majesty in Right of Canada as Rep. by Agriculture and Agri-Food Canada (B) STREET: Experimental Farm (C) CITY: Ottawa (D) STATE: Ontario (E) COUNTRY: Canada (F) POSTAL CODE (ZIP): KlA 0C6 (ii) TITLE OF INVENTION: Production of Value-added Milk by Incorpoartion of Specific DNA Sequences into Mammary Epithelial Cells (iii) NUMBER OF SEQUENCES: 4 (iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO) (v) CURRENT APPLICATION DATA:
APPLICATION NUMBER: CA 0,000,000 (vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: CA 2,199,212 (B) FILING DATE: 05-MAR-1997 (2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7699 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CA 02224l08 l998-02-24 CA 02224l08 l998-02-24 TAATCCGAAC AGGCCCTGGT GGGA~AGATA CCAGCCCATC AGCTACAAGA TCTGCAGTCG 1920 CA 02224l08 l998-02-24 CA 02224l08 l998-02-24 AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAACCACC GCTGGTAGCG GTG~'llllll 6420 CA 02224l08 l998-02-24 (2) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7980 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

CA 02224l08 l998-02-24 TAATCCGAAC AGGCCCTGGT GGGA~AGATA CCAGCCCATC AGCTACAAGA TCTGCAGTCG 1920 CA 02224l08 l998-02-24 CA~ACTGCAC GATCTAAATA CTCAGTGGTT TTCAGCAGGA ACGA~ACCCT TTATTTACCA 2400 GTACGGGTTC ACACGGGTGA TGTCAAGTTA TCGTTGGCCA AGATATTTCG A~AACGGAGT 2760 ACTGGCCGAA GCCGCTTGGA ATA~GGCCGG TGTGTGTTTG TCTATATGTG ATTTTCCACC 3360 ATATTGCCGT CTTTTGGCAA TGTGAGGGCC CGGA~ACCTG GCCCTGTCTT CTTGACGAGC 3420 CA 02224l08 l998-02-24 CA 02224l08 l998-02-24 GTATTTGGTA TCTGCGCTCT GCTGAAGCCA GTTACCTTCG GAAA~AGAGT TGGTAGCTCT 6660 CA 02224l08 l998-02-24 (2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7311 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

CA 02224l08 l998-02-24 CA 02224l08 l998-02-24 TTTAGTACTA TTTTTACTCA AATTCAGAAG TTAGAAATGG GAATAGAAAA TAGAhAGAGA 3300 AAGGGAAAAA AGA~'l'~'l"l"l"l' TGTCAAAATA GGAGACAGGT GGTGGCAACC AGGGACTTAT 3420 CA 02224l08 l998-02-24 CA 02224l08 l998-02-24 -CAGGGTTATT GTCTCATGAG CGGATACATA TTTGAATGTA TTTAGAAAAA TA~ACA~ATA 7200 (2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7885 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

TCGCGGGCTT CTGCCTCTTA GACCACTCTA CCCTATTCCC CACACTCACC GGAGCCA~AG 120 CGATAGACTG CGTCGCCCGG GTACCCGTAT TCCCAATA~A GCCTCTTGCT GTTTGCATCC 660 CA 02224l08 l998-02-24 CA 02224l08 l998-02-24 GACCCGTCTG CGCACAAACG GATGAGCCCA TCAGACA~AG ACATATTCAT TCTCTGCTGC 2940 AATAAGACCA ATCCAATAGG TAGATTATTA GTTACTATGT TAAGA~ATGA ATCATTATCT 3240 TTTAGTACTA TTTTTACTCA AATTCAGAAG TTAGAAATGG GAATAGAAAA TAGA~AGAGA 3300 ll'lllllGTT TGCAAGCAGC AGATTACGCG CAGAAAAAAA GGATCTCAAG AAGATCCTTT 6660 AAGGCGAGTT ACATGATCCC CCA'l~'ll~lG CAAAAAAGCG GTTAGCTCCT TCGGTCCTCC 7260 ..

CATATTTGAA TGTATTTAGA AAAATAAACA AATAGGGGTT CCGCGCACAT TTCCCCGA~A 7800

Claims (23)

1) A method of producing a trans-somatic mammal, wherein said method provides the incorporation of a DNA sequence into the secretory cells of the mammary gland to alter the composition of the milk, wherein said method comprising the steps of:
a) providing a vector containing a DNA sequence encoding a valuable compound;
b) packaging said vector into a cell line;
c) preparing a solution comprising the packaged vector and cell line producing said packaged vector; and d) delivering said solution into the mammary gland to allow the incorporation ofthe DNA into the secretory cells of the mammary gland.

2) The method of Claim 1, wherein the method further comprises the step of flushing the mammary gland with an osmotically-balanced solution prior to delivering the said solution into the mammary gland.

3) The method of Claim 2, wherein the method further comprises the step of externally massaging the mammary gland several times a day after delivering the said solution into the mammary gland.

4) The method of Claim 2, wherein the method further comprises the step of growing the cells producing said packaged vector on a solid support means, and the solution comprises the cells on said support means and the packaged vector.

5) The method of Claim 4, wherein the method further comprises the step of externally massaging the mammary gland several times a day after delivering the said solution into the mammary gland.

6) The method of Claim 2 or 4, wherein a substance, with a density higher than the density of the solution, is delivered into the mammary gland after the delivery of the solution, wherein said substance displaces the solution upwards in the mammary gland.

7) The method of Claim 1, wherein the valuable compound is a pharmaceutical.

8) The method of Claim 7, wherein the pharmaceutical is a compound selected from the group consisting of: a tissue plasminogen activator, an antibody, an antibiotic, a blood clotting factor, galactosyltransferase, a growth factor, an oncoprotein, a hormone, a milk protein, a hormone receptor, a tumor suppressor protein, a vaccine and an erythropoietin.

9) The method of Claim 8, wherein the pharmaceutical is a tissue plasminogen activator.

10) The method of Claim 1, wherein the vector is transiently transfected into PA317 cells;
the resulting particles are harvested and trans-infected into PG13 cells.

11) The method of Claim 1, wherein the vector is selected from the group pL(X)SH, pL(X)SN, pLNS(X), pLHS(X), pLNC(X), pLHC(X), pLNA(X) and pLHA(X); wherein "A" isthe beta actin promoter, "L" is the moloney murine virus long terminal repeat (LTR), "S" is the SV40 promoter, "C" is the cytomegalovirus promoter and "X" is a DNA sequence encoding a valuable compound.

12) The method of Claim 1, wherein the vector is selected from the group consisting of pL(X)iN and pL(X)iH; wherein "I" is an internal ribosomal entry site (IRES) and "X" is a DNA sequence encoding a valuable compound.

13) The method of Claim 1, wherein the vector is pLNM(X); wherein "M" is a mousemammary tumor virus promoter and "X" is a DNA sequence encoding a valuable compound.

14) The method of Claim 1, wherein the vector is pLNMi2(X); wherein "M" is a mouse mammary tumor virus promoter, "i2" is a modified wild type internal ribosomal entry site and "X" is a DNA sequence encoding a valuable compound.

15) The method of Claims 11 to 14, wherein "X" is a DNA sequence encoding a tissue plasminogen activator.

16) The method of Claim 1, wherein the solution is an aqueous solution.

17) The method of Claim 2, wherein the osmotically-balanced solution is a saline solution.

18) The method of Claim 4, wherein the solid support means is a matrix selected from the group consisting of Cytodex beads or Cultisphere.

19) The method of Claim 6, wherein said substance is a silicone substance.

20) The method of Claim 1, wherein the vector is transfected into a packaging cell line producing a non-retroviral derived particle.

21) The method of Claim 1, wherein the vector is transfected into a packaging cell line producing a retroviral derived particle.

22) The method of Claim 1, wherein the trans-infecting particle is produced in vitro.

23) The method of Claim 1, wherein the trans-infecting particle is produced in vivo.